Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
We are a biopharmaceutical company focused on unlocking the potential of new and existing drugs.
We began leveraging decades of clinical experience and a goal to transform the care of debilitating medical and mental health conditions. Here is the story…
Completed $7.3M Series A Financing.
Successful Pre-IND FDA guidance for BB106 to treat acute pain.
Drug Delivery Innovation Awards – Partnership Category
2022 Universe of Pre-Filled Syringes and Injection Devices Conference, Palm Springs, CA on October 18, 2022
Developing our BB106 non-opioid therapy for pain management and leveraging our growing platform are the focus of our R&D.
Bexson is poised to disrupt the $189 billion (growing to $347 billion by 2030) injectable drug delivery market.
Our technology can provide pharmacokinetic solutions for new and existing drugs across a broad range of therapeutic areas.
Our experienced team has a strong background in health innovation, clinical development and IP creation. Expertise in Pharma with over 20 FDA Approvals and Leaders in Med-Tech Device Development with more than 130 US Patents.
We are developing a formulation technology platform & a subcutaneous delivery platform for controlled delivery of critical medications in need of pharmacokinetic innovation.
